Literature DB >> 16254038

Expression of tumor suppressor and tumor-related proteins in differentiated carcinoma, undifferentiated carcinoma with tubular component and pure undifferentiated carcinoma of the stomach.

Teiichiro Honda1, Gen Tamura, Yasushi Endoh, Satoshi Nishizuka, Sumio Kawata, Teiichi Motoyama.   

Abstract

BACKGROUND: The recent development of tissue microarray (TMA) technology allows high-throughput protein expression profiling of cancer tissues by immunohistochemistry. We attempted to clarify the derivation of undifferentiated-type gastric carcinoma with tubular component by using TMA.
METHODS: We constructed a TMA system composed of six paraffin blocks in which 274 samples of formalin-fixed gastric carcinoma tissue from 274 patients were embedded. Using this system, we performed immunohistochemical stains for five tumor suppressor and tumor-related proteins, i.e. p53, p16, hMLH1, c-erbB-2 and carcinoembryonic antigen (CEA). The 274 gastric carcinomas were histopathologically divided into the following three groups according to the degree of differentiation: differentiated-type (D-type), undifferentiated-type with tubular component (UT-type) and pure undifferentiated-type (UP-type). Immunohistochemical results were then compared with histological types.
RESULTS: The percentages of abnormal expression of each protein in D-type, UT-type and UP-type carcinomas were as follows: 27% (38/143), 17% (17/98) and 15% (5/33) for p53; 27% (39/143), 19% (19/98) and 18% (6/33) for p16; 38% (54/143), 44% (43/98) and 24% (8/33) for hMLH1; 15% (22/143), 5% (5/98) and 0% (0/33) for c-erbB-2; and 22% (31/143), 35% (34/98) and 70% (23/33) for CEA. UP-type carcinomas exhibited the lowest frequencies of abnormal expression for p53, p16, hMLH1 and c-erbB-2, but the highest frequencies for CEA. UT-type carcinomas generally showed intermediate frequencies between those of D-type and UP-type carcinomas. Differences between D-type and UP-type for c-erbB-2 (P < 0.05) and CEA (P < 0.001) were significant, as were differences between D-type and UT-type for c-erbB-2 (P < 0.05) and CEA (P < 0.05), and differences between UT-type and UP-type for hMLH1 (P < 0.05) and CEA (P < 0.001).
CONCLUSIONS: These findings reveal that gastric carcinomas have distinct expression profiles for tumor suppressor and tumor-related proteins depending on histological types, and support the hypothesis that UT-type carcinomas are derived not only from D-type but also from UP-type carcinomas. We also found significant differences between abnormal protein expression and other clinicopathological parameters such as gender, age and status of tumor and nodes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16254038     DOI: 10.1093/jjco/hyi166

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  4 in total

1.  Helicobacter pylori Modulated Host Immunity in Gastric Cancer Patients With S-1 Adjuvant Chemotherapy.

Authors:  Yuka Koizumi; Sheny Ahmad; Miyuki Ikeda; Akiko Yashima-Abo; Ginny Espina; Ryo Sugimoto; Tamotsu Sugai; Takeshi Iwaya; Gen Tamura; Keisuke Koeda; Lance A Liotta; Fumiaki Takahashi; Satoshi S Nishizuka
Journal:  J Natl Cancer Inst       Date:  2022-08-08       Impact factor: 11.816

2.  Mixed Carcinoma as an Independent Prognostic Factor in Submucosal Invasive Gastric Carcinoma.

Authors:  Hyung Kyu Park; Kyung-Yung Lee; Moon-Won Yoo; Tae Sook Hwang; Hye Seung Han
Journal:  J Korean Med Sci       Date:  2016-04-11       Impact factor: 2.153

3.  Clinicopathological features and differential diagnosis of gastrofibromatosis-like undifferentiated carcinoma.

Authors:  Zhishang Zhang; Guang Zhao; Bo Jiang; Baohui Li; Yangkun Wang
Journal:  J Int Med Res       Date:  2020-12       Impact factor: 1.671

4.  Molecular marker identification for relapse prediction in 5-FU-based adjuvant chemotherapy in gastric and colorectal cancers.

Authors:  Kazushige Ishida; Satoshi S Nishizuka; Takehiro Chiba; Miyuki Ikeda; Kohei Kume; Fumitaka Endo; Hirokatsu Katagiri; Teppei Matsuo; Hironobu Noda; Takeshi Iwaya; Noriyuki Yamada; Hisataka Fujiwara; Masanori Takahashi; Tetsuya Itabashi; Noriyuki Uesugi; Chihaya Maesawa; Gen Tamura; Tamotsu Sugai; Koki Otsuka; Keisuke Koeda; Go Wakabayashi
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.